HomeAI · summaries
Storia in 2 fonti
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private p…Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private placement to advance PACAP-targeting migraine drugs.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
A migraine drugmaker heads to the public markets through reverse merger
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing…
- ·
endpoints.news
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private p…Paragon…